Scientists discover why Ozempic and Wegovy weight loss eventually plateaus
New research from the NIH has revealed insights into why weight loss from GLP-1 drugs like Ozempic and Wegovy plateaus over time. The study found that the effects of semaglutide on appetite-controlling brain cells vary among individuals and can diminish as neurons adapt. Researchers also identified potential methods to extend the drug's effectiveness, which may help patients overcome weight loss plateaus.
- ▪NIH researchers discovered that semaglutide affects brain cells differently, leading to varied weight loss responses.
- ▪The study showed that some neurons maintain elevated cAMP levels longer than others when treated with semaglutide.
- ▪Using the drug roflumilast, scientists were able to prolong the signaling effects of semaglutide in neurons.
Opening excerpt (first ~120 words) tap to expand
Science News from research organizations Scientists discover why Ozempic and Wegovy weight loss eventually plateaus Date: May 25, 2026 Source: NIH/Office of the Director Summary: New NIH research reveals that semaglutide sparks different responses inside appetite-controlling brain cells, offering fresh insight into why GLP-1 weight-loss drugs don’t work the same for everyone. Scientists also found a possible way to extend the drugs’ effects, potentially helping patients push past weight-loss plateaus. Share: Facebook Twitter Pinterest LinkedIN Email FULL STORY Scientists may have discovered why GLP-1 weight-loss drugs eventually plateau — and how to make them work longer.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at ScienceDaily.
Discussion
0 commentsMore from ScienceDaily
